Shedding light on the asparaginase galaxy

Blood

Volumn 123, Issue 13, 2014, Pages 1976-1978

  Rizzari, Carmelo ^a  

^a San Gerardo Hospital   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; ASPARAGINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; NOTE; PHYSICIAN; PLASMA; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; DRUG MONITORING; ERWINIA; FEMALE; HUMANS; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84897502425     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-553040     Document Type: Note

References (10)

1. Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026-2033.
2. Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer. 2010;54(7):952-958.
3. Panosyan EH, Seibel NL, Martin-Aragon S, et al; Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217-226. (Pubitemid 38500969)
4. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202-1210.
5. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24-31. (Pubitemid 43235382)
6. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629. (Pubitemid 129735360)
7. Müller HJ, Löning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110(2):379-384. (Pubitemid 30646864)
8. AIEOP-BFM ALL. 2009. International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). NLM Identifier: NCT01117441. Available from: http://clinicaltrials.gov/show/ NCT01117441. Accessed February 20, 2014.
9. Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122(4):507-514.
10. Willer A, Gerss J, König T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118(22):5774-5782.